Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Are you using maintenance lurbinectedin with immunotherapy in the first-line treatment of extensive stage small cell lung cancer?
Related Questions
Would you consider using Elahere for patients with FOLR1-positive metastatic lung adenocarcinoma?
For a patient with NSCLC harboring an EGFR or ALK mutation that transforms into SCLC, would you add immunotherapy to chemotherapy or avoid immunotherapy given the tumor's EGFR/ALK origin?
Would you add immunotherapy to chemotherapy for a patient with metastatic NSCLC, an atypical EGFR mutation, and PD-L1 ≥50% who has progressed on osimertinib?
Is concurrent immuno-radiation therapy a viable treatment option for patients with unresectable, non-metastatic, locally advanced lung cancer, who have high PD-L1 expression and no oncogenic mutations?
In a patient with potentially resectable lung cancer experiencing severe pain due to chest wall invasion, would you consider palliative radiation therapy prior to neoadjuvant/perioperative chemoimmunotherapy?
Would you switch from carboplatin/etoposide to cisplatin/etoposide in an LS-SCLC patient who initially declines cisplatin but subsequently agrees to it?
Is DLL3 expression necessary for tarlatamab efficacy in small cell lung cancer?
How does metaplastic thymoma histology impact your decision regarding adjuvant radiation?
Can Dupixent and Durvalumab be used at the same time in a patient with extensive stage small cell lung cancer?
What are the main practical factors to consider when using bispecific antibody therapy (Tarlatamab) for extensive-stage small cell lung cancer?
